MedTrace Logo

Maximizing Visual Outcomes With Eyhance IOLs

NCT05611073 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2025-05-23

Study results available
· View outcomes & findings →

Summary

This is a non-interventional prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had bilateral implantation of an Eyhance IOL at the time of cataract surgery. These patients will then be compared to assess which patient biometric properties (such as spherical aberration, q value, pupil size, etc.) lead to an overall increase in near or intermediate vision as well as overall patient satisfaction.

Conditions

  • Pseudophakia

Interventions

DIAGNOSTIC_TEST

Visual Acuity

Measurement of distance, intermediate and near visual acuity.

DIAGNOSTIC_TEST

Biometric Data Collection

Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.

OTHER

Patient Questionnaire

Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.

Sponsors & Collaborators

  • Berkeley Eye Center

    lead OTHER

Principal Investigators

  • Morgan Micheletti, MD · Berkeley Eye Center

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-07
Primary Completion
2022-11-07
Completion
2022-11-07
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05611073 on ClinicalTrials.gov